Health Trials

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

3

Review clinical trials related to Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Participants needed: 762
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jul 13, 2026Locations: 317
Eligibility criteria

Males or non-pregnant females aged between 18 and 75 years (inclusive) at time o... [+3]

Liver disorder other than MASH. [+5]

Read more
Status: Recruiting

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).

Participants needed: 762
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: 89bio, Inc.Updated: Jun 4, 2026Locations: 303
Eligibility criteria

Males or non-pregnant females aged between 18 and 75 years (inclusive) at time o... [+3]

Liver disorder other than MASH. [+5]

Read more
Status: Recruiting

Evaluating the Pharmacokinetics and Safety of Miricorilant

A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Participants needed: 15
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Corcept TherapeuticsUpdated: May 26, 2026Locations: 1
Eligibility criteria

Nonalcoholic fatty liver disease (NAFLD) activity score (NAS) ≥ 3 with at least... [+8]

Women who are pregnant, planning to become pregnant, or are lactating. [+9]

Read more